Lymphoma, Leukemia Patients Sought for Trial of MoAb

April 1, 1996

BOSTON--Researchers at New England Deaconess Hospital are seeking patients with Hodgkin's disease, non-Hodgkin's lymphoma, acute myelogenous leukemia (AML), and chronic myelogenous leukemia (CML) for an FDA-sponsored study of a humanized anti-Tac (interleukin-2 receptor) monoclonal antibody. The phase Ib/II multidose trial will study tolerance, therapeutic efficacy, and biological efficacy.

BOSTON--Researchers at New England Deaconess Hospital are seekingpatients with Hodgkin's disease, non-Hodgkin's lymphoma, acutemyelogenous leukemia (AML), and chronic myelogenous leukemia (CML)for an FDA-sponsored study of a humanized anti-Tac (interleukin-2receptor) monoclonal antibody. The phase Ib/II multidose trialwill study tolerance, therapeutic efficacy, and biological efficacy.

The protocol (92-0205-34) calls for patients over the age of 18with a life expectancy greater than 2 months and confirmed Tacon malignant cells, except for Hodgkin's disease patients, forwhich all R-S (Reed-Sternberg) cells are Tac-positive. Also, patientsmust be able to have continuous local access for 1 month.

Hodgkin's disease patients (25 to be enrolled) must have failedfirst-line therapy and one salvage attempt. Non-Hodgkin's lymphomapatients with aggressive disease must have failed first-line therapy;if indolent, any patient is eligible. All CML patients (eightto be enrolled) are eligible. AML patients (eight to be enrolled)must have failed first-line therapy or be in first or later relapse.

For more information, contact Dan Hagg, New England DeaconessHospital, 21-27 Burlington Avenue, 5th Floor, Boston, MA 02215.Phone: 617-632-0316.